Search results
Results from the WOW.Com Content Network
Lecanemab was jointly developed by Eisai and Biogen. It was granted accelerated approval for medical use in the United States in January 2023, [ 27 ] and fully approved by the FDA in July 2023. [ 24 ] [ 28 ] Lecanemab was approved for medical use in South Korea in May 2024, [ 29 ] and in Mexico in December 2024.
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. [ 2 ] [ 4 ] Lecanemab is an amyloid beta -directed antibody. [ 2 ] It is given via intravenous infusion to patients with mild cognitive impairment or mild dementia. [ 2 ]
My memory assessments have been unchanged since I started on lecanemab.” The retired business executive first noticed problems with his memory in 2016, when he was finding it difficult to absorb ...
Editor’s Note: “Dr. Sanjay Gupta Reports: The Last Alzheimer’s Patient” airs at 8 p.m. ET Sunday, July 7, on CNN. The US Food and Drug Administration on Tuesday approved donanemab, a ...
For premium support please call: 800-290-4726 more ways to reach us
The US Food and Drug Administration (FDA) label for donanemab contains a boxed warning about amyloid-related imaging abnormalities. [1]Side effects may include infusion-related reactions, with symptoms such as flu-like symptoms, nausea, vomiting and changes in blood pressure, and hypersensitivity reactions, including anaphylaxis (severe, life-threatening allergic reaction) and angioedema ...
Lecanemab was associated with a type of brain swelling in 12.6% of trial patients, a side effect previously seen with similar drugs. 17.3% of patients had microhemorrhages in the brain— a ...
Lecanemab: To treat Alzheimer's disease [4] Miglustat: Nedosiran: To lower urinary oxalate levels in primary hyperoxaluria type 1 and relatively preserved kidney function [4] Nirogacestat: To treat desmoid tumors [4] Pembrolizumab: Sutimlimab: Talquetamab: To treat relapsed or refractory multiple myeloma after at least four therapies [4 ...